Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study (Q46297341)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study |
scientific article |
Statements
1 reference
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study (English)
1 reference
1 reference
Dafna Gladman
1 reference
Arthur Kavanaugh
1 reference
Philip Mease
1 reference
Gerald G Krueger
1 reference
Juan Gomez-Reino
1 reference
Kim Papp
1 reference
Julie Zrubek
1 reference
Surekha Mudivarthy
1 reference
Michael Mack
1 reference
Sudha Visvanathan
1 reference
Anna Beutler
1 reference
1 April 2009
1 reference
1 reference
60
1 reference
976-986
1 reference
4
1 reference
Identifiers
1 reference
1 reference